Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884096 | 0.83 | MAPT (0.51) | KDM4EMAPTTHRBNAMPTPDE4B | |
| SCHEMBL23411311 | 0.83 | NAMPT (0.49) | KDM4EMAPTTHRBNAMPTPDE4B | |
| SCHEMBL29891481 | 0.83 | NAMPT (0.49) | KDM4EMAPTTHRBNAMPTPDE4B | |
| SCHEMBL31728977 | 0.83 | NAMPT (0.49) | KDM4EMAPTTHRBNAMPTPDE4B | |
| SCHEMBL13625518 | 0.82 | PDE4B (0.48) | KDM4EMAPTTHRBPDE4BGPR119 | |
| SCHEMBL1071461 | 0.82 | PDE4B (0.48) | KDM4EMAPTTHRBPDE4BGPR119 | |
| SCHEMBL1518501 | 0.82 | PDE4B (0.48) | KDM4EMAPTTHRBPDE4BGPR119 | |
| SCHEMBL1071462 | 0.82 | PDE4B (0.48) | KDM4EMAPTTHRBPDE4BGPR119 | |
| SCHEMBL1071459 | 0.82 | PDE4B (0.48) | KDM4EMAPTTHRBPDE4BGPR119 | |
| SCHEMBL23411339 | 0.79 | KDM4E (0.52) | KDM4EMAPTTHRBNAMPTPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MSD K.K. (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MC1R, MCHR1, MCHR2 | KDM4E 2707/4885MAPT 3948/4885THRB 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.